As a global human data science company IQVIA is at the forefront of unlocking the potential of health data to drive key advancements for future health improvements and delivering transformative benefits to improved population outcomes. IQVIA believes that the value of unlocking data is in the clinical and strategic decision-making it can inform and, as a trusted partner to health systems and providers, we use our extensive data and analytics capabilities to transform health outcomes and deliver pioneering biomedical research.
An example of this is how, through using our data analytics capabilities and clinical expertise, we have risk assessed populations and implemented targeted interventions, resulting in reduced emergency admissions and improved patient outcomes – addressing a key challenge faced by all health systems.
95% NHS organisations already use one or more of our services including costing, coding, benchmarking and data warehousing and our insights and feedback expertise is widespread across a range of healthcare systems.
Demonstrating our ability to deliver at speed, within two weeks of the request, IQVIA operationalised and ran the UK Government COVID Infection Survey, underpinned by our real-world data platform and the mobilisation of 4,000 field workers to undertake testing, enabling real-time population health data that informed national emergency responses.
Also, as a major investor in UK life sciences we consistently attract commercial clinical trials in cancer, neurology, paediatrics, and rare disease to the UK, making IQVIA the third largest life sciences employer and contributing over £2.2 billion to the UK economy.
IQVIA’s success is enhanced by creating these valuable connections and collaborations between life sciences and the wider HCS. Our expertise and unique capabilities mean we are best placed to partner with the HCS to deliver improved outcomes.
